IL101928A0 - Methods of treatment of motor neuron diseases using members of the bdnf/nt-3/ngf family of molecules - Google Patents

Methods of treatment of motor neuron diseases using members of the bdnf/nt-3/ngf family of molecules

Info

Publication number
IL101928A0
IL101928A0 IL101928A IL10192892A IL101928A0 IL 101928 A0 IL101928 A0 IL 101928A0 IL 101928 A IL101928 A IL 101928A IL 10192892 A IL10192892 A IL 10192892A IL 101928 A0 IL101928 A0 IL 101928A0
Authority
IL
Israel
Prior art keywords
bdnf
treatment
motor neuron
molecules
members
Prior art date
Application number
IL101928A
Other languages
English (en)
Original Assignee
Max Planck Gesellschaft
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft, Regeneron Pharma filed Critical Max Planck Gesellschaft
Publication of IL101928A0 publication Critical patent/IL101928A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Physical Water Treatments (AREA)
  • Water Treatment By Electricity Or Magnetism (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
  • Separation Of Suspended Particles By Flocculating Agents (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Water Treatment By Sorption (AREA)
  • External Artificial Organs (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL101928A 1991-07-10 1992-05-19 Methods of treatment of motor neuron diseases using members of the bdnf/nt-3/ngf family of molecules IL101928A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US72770491A 1991-07-10 1991-07-10

Publications (1)

Publication Number Publication Date
IL101928A0 true IL101928A0 (en) 1992-12-30

Family

ID=24923677

Family Applications (1)

Application Number Title Priority Date Filing Date
IL101928A IL101928A0 (en) 1991-07-10 1992-05-19 Methods of treatment of motor neuron diseases using members of the bdnf/nt-3/ngf family of molecules

Country Status (20)

Country Link
EP (2) EP0593516B1 (de)
JP (1) JPH06509094A (de)
CN (1) CN1065768C (de)
AT (1) ATE202939T1 (de)
AU (2) AU675409B2 (de)
CA (1) CA2113083A1 (de)
DE (1) DE69231930T2 (de)
DK (1) DK0593516T3 (de)
ES (1) ES2157903T3 (de)
FI (1) FI940098A7 (de)
GR (1) GR3036776T3 (de)
HU (1) HUT70275A (de)
IE (1) IE921602A1 (de)
IL (1) IL101928A0 (de)
NO (1) NO940084L (de)
PT (1) PT100501A (de)
RU (1) RU94016525A (de)
SK (1) SK2694A3 (de)
WO (1) WO1993001300A1 (de)
ZA (1) ZA923639B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4535993A (en) * 1992-06-12 1994-01-04 Regeneron Pharmaceuticals, Inc. Therapeutic and diagnostic methods based on neurotrophin-4 expression
FR2717496B1 (fr) * 1994-03-18 1996-04-12 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
CN1112215C (zh) * 1999-12-28 2003-06-25 潘晓东 神经生长因子在治疗有机溶剂中毒性周围神经病中的用途
US7741310B2 (en) 2000-05-05 2010-06-22 Research Foundation Of The City University Of New York Methods for stimulating nervous system regeneration and repair by regulating arginase I and polyamine synthesis
WO2008156418A1 (en) * 2007-06-19 2008-12-24 Astrazeneca Ab A method for screening or diagnosis of postpolio syndrome and fibromyalgia
MY161564A (en) * 2007-08-10 2017-04-28 Regeneron Pharma High affinity human antibodies to human nerve growth factor
WO2014111525A2 (en) 2013-01-18 2014-07-24 Anaxomics Biotech, Sl New combination therapies for treating nervous system diseases
WO2016210325A1 (en) 2015-06-26 2016-12-29 C.R. Bard, Inc. Connector interface for ecg-based catheter positioning system
US20250170212A1 (en) * 2022-02-28 2025-05-29 Bioincept, Llc Compositions and methods of treating amyotrophic lateral sclerosis (als) and related disorders
GB202303495D0 (en) * 2023-03-09 2023-04-26 Ucl Business Ltd Therapy for charcot-marie-tooth disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923696A (en) * 1987-05-04 1990-05-08 Baylor College Of Medicine Method to prepare a neurotrophic composition
US5229500A (en) * 1989-08-30 1993-07-20 Regeneron Pharmaceuticals, Inc. Brain derived neurotrophic factor
IL95511A (en) * 1989-08-30 2000-10-31 Max Planck Gesellschaft Neurotrophin-3 a novel neurotrophic factor related to nerve growth and brain derived neurotrophic factor
IE903130A1 (en) * 1989-09-15 1991-03-27 Regeneron Pharma Ciliary neurotrophic factor

Also Published As

Publication number Publication date
RU94016525A (ru) 1996-06-10
GR3036776T3 (en) 2002-01-31
EP0593516B1 (de) 2001-07-11
AU675409B2 (en) 1997-02-06
FI940098A7 (fi) 1994-03-10
SK2694A3 (en) 1995-02-08
EP0593516A4 (de) 1995-01-18
NO940084L (no) 1994-03-08
CN1065768C (zh) 2001-05-16
FI940098A0 (fi) 1994-01-10
IE921602A1 (en) 1993-01-13
CN1071585A (zh) 1993-05-05
DK0593516T3 (da) 2001-09-17
ATE202939T1 (de) 2001-07-15
ZA923639B (en) 1993-02-24
DE69231930D1 (de) 2001-08-16
HU9400063D0 (en) 1994-06-28
EP0755682A1 (de) 1997-01-29
NO940084D0 (no) 1994-01-10
DE69231930T2 (de) 2002-04-11
HUT70275A (en) 1995-09-28
JPH06509094A (ja) 1994-10-13
AU7067696A (en) 1997-01-16
PT100501A (pt) 1993-09-30
AU2009592A (en) 1993-02-11
WO1993001300A1 (en) 1993-01-21
ES2157903T3 (es) 2001-09-01
EP0593516A1 (de) 1994-04-27
CA2113083A1 (en) 1993-01-21

Similar Documents

Publication Publication Date Title
FI108146B (fi) Biologisesti aktiivisten, neurotrofisten NGF/BDNF-sarjan yhdistelmäproteiinien valmistus
ZA923639B (en) Methods of treatment of motor neuron diseases using members of the bdnf/nt-3/ngf family of molecules
NO951592L (no) Fremgangsmåte for fremstilling av et transdermalt terapeutisk system
AU2172588A (en) Conjugates of cytokines with immunoglobulins
DE69331605D1 (de) Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen
ITMI930699A1 (it) Derivati dell'indolo utili nel trattamento dei disturbi del sistema nervoso centrale
ATE199167T1 (de) Nichtglykosyliertes fgf-4 und dieses enthaltende präparate
GR3025134T3 (en) Process for preparing a concentrate of blood coagulation factor XI with high specific activity, appropriate for therapeutic use
Gordon The relationship between language and behaviour.
AU7426487A (en) Method of treating depression using d-fenfluramine
MD1716B2 (en) Use of melatonin for treatment of patients dependent on benzodiazepine
Metter et al. Theoretical, Clinical, Research, and Ethical Constraints of the Eye Movement Desensitization Reprocessing Technique.
Aurela A systematic storytelling therapy.
Dienstfrey Neal Miller, the dumb autonomic nervous system, and biofeedback.
Eletsky Effect of hemosorption on the time-course of neuropsychic disturbances in patients with psoriasis and neurodermatitis.
Repo The holistic approach to rehabilitation: a commentary
Fath The special ministry in long term care
ROBINSON Comments on Ethical Protocol
Goldenring Comments on Ethical Protocol
Mendelevich et al. Age peculiarity of anticipated mechanisms of neurosogenesis
翁嘉颖 et al. THE MECHANISM AND THE EFFECTS OF CHINESE TRADITIONAL MASSAGE TREATMENT ON TRAUMATIC LUMBAR PAIN
UA19521A (uk) Спосіб лікуваhhя періhатальhих ушкоджеhь мозку дітей
AU6725387A (en) Drugs for the treatment and cure of all infectious diseases caused by pathogenic virulent micro-organisms
UA10219A (uk) Спосіб лікування туберкульозу легень